Uncategorized

Denali sells FDA voucher for $195M to support neurodegenerative pipeline

Published

5 hours ago

on

June 19, 2026

By

Temp User

Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Endpoints News3 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State
Uncategorized3 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion

Exit mobile version